9th Symposium

26/28 May 2016

Practical focus on the diagnosis and treatment of the psychiatric and neuropsychological aspects of HIV-infected patients.

Dora Brites, Pharm.D., Ph.D.

Research Institute for Medicines (iMed.ULisboa). Lisbon University. Portugal

Neuroinflammation in depression: microglia activation and dysfunction

Andrea Calcagno, M.D., DTM&H

University of Torino, Italy

The impact of antiretroviral therapy on central nervous system: two sides of the same coin

Sarah Joseph, M.D.

Department of Microbiology & Immunology. University North Carolina. Chapel Hill, USA.

Central nervous system as a reservoir for HIV: why it happens and what can be done

Marta Boffito, M.D., Ph.D.

St Stephen’s AIDS Trust. Chelsea and Westminster Hospital and Imperial College, London, United Kingdom.

Substance abuse in HIV-infected patients: what the clinicians should know

Adriana S. Carvalhal, M.D.

Department of Psychiatry, University of Toronto and Medical Psychiatry Consultation Service, St. Michael’s hospital. Toronto, Canada.

Differential diagnosis between depression and neurocognitive impairment in HIV-infected persons

Alan Winston, M.D.

St. Mary’s Hospital. London, United Kingdom

Emerging neurological toxicities in HIV

Mr. David Stuart

Substance Use, 56 Dean Street. Chelsea and Westminster NHS Foundation Trust. London, United Kingdom.

Sexuality, substance use and HIV

Scott Letendre, M.D.

University of California. San Diego, USA

Update for the Conference on Retroviruses and Opportunistic Infections and Summary of the Symposium

Oral Communications. Session 1

Oral Communications. Session 2

Round Table

Antiretroviral therapy cardiovascular disease and neurocognitive impairment.